Sinovac Holds 2013 Annual General Meeting of Shareholders
BEIJING, Aug. 21, 2013
BEIJING, Aug. 21, 2013 /PRNewswire/-- Sinovac Biotech Ltd. (SVA), a leading
provider of biopharmaceutical products in China, announced today that it held
its 2013 Annual General Meeting of Shareholders on Wednesday, August 21, 2013
at 9:00 a.m. Beijing Time. The required quorum, a majority of the common
shares outstanding, was voted by proxy. The meeting was held at No. 39 Shangdi
Xi Road, Haidian District, Beijing, PRC.
During the meeting, the three proposals that required the affirmative vote of
a majority of the shares cast were approved as follows:
oApprove the re-election of Weidong Yin, Yuk Lam Lo, Simon Anderson,
Kenneth Lee and Meng Mei as the Company's directors until the next annual
meeting of shareholders and or until their successors are duly elected;
oApprove the audited consolidated financial statements of the Company for
the financial year ended December 31, 2012 together with the Report of
Independent Registered Public Accounting Firm thereon and the notes
oApprove the appointment of Ernst &Young Hua Ming LLP as the independent
auditor of the Company for the fiscal year ending December 31, 2013 and to
authorize the directors of the Company to fix such independent auditor's
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease) and filed new drug application with China Food &
Drug Administration.In 2009, Sinovac was the first company worldwide to
receive approval for its H1N1 influenza vaccine, Panflu.1, and has
manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program.The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee
Sinovac Biotech Ltd.
The Ruth Group
The Ruth Group
SOURCE Sinovac Biotech Ltd.
Press spacebar to pause and continue. Press esc to stop.